Mr. John Gevisser reports

MEDX ANNOUNCES APPLICATION FOR FINAL EXTENSION OF NON-BROKERED PRIVATE PLACEMENT

Further to MedX Health Corp.'s press release dated March 16, 2026, when it announced application for an extension of time within which to effect further closings of the non-brokered private placement to accredited investors of Series IV convertible loan notes originally announced in its press release dated Feb. 2, 2026, and the first closing, which was announced in its press release of Feb. 27, 2026, MedX Health has made application to the TSX Venture Exchange for a final extension of 30 days to May 15, 2026, within which to effect further closings on this private placement of Series IV convertible loan notes. The initial closing, effective Feb. 27, 2026, comprised the issuance of $2.7-million of Series IV notes. With the proposed extension of the final date for this placement, it is anticipated that further closings will take place, for up to a maximum of a further $2.3-million of Series IV notes. The Series IV notes bear interest at 6 per cent per year, payable quarterly, and mature on Dec. 31, 2028. The Series IV notes may be converted, at the option of the holder, into units at 10 cents per unit at any time until the maturity date. Each unit will comprise one fully paid common share and one-half of a share purchase warrant. Each whole share purchase warrant will be exercisable to purchase one further common share at the price of 12.5 cents, exercisable for a period expiring on the maturity date. Holders of Series I convertible loan notes, who wish to do so, will be able to surrender their Series I notes by way of subscription for Series IV notes. The Series I notes matured on Dec. 31, 2025, and their terms were similar to the Series IV notes, except that the conversion price was 14 cents and the warrant exercise price was 20 cents. Qualified agents will receive a cash commission equal to 6 per cent of the gross proceeds received by the company from the sale of the units to subscribers introduced by such agent(s) and agent warrants equal to 6 per cent of subscriptions introduced by such agent(s). Each agent's warrant, which will be non-transferable, will entitle the holder to acquire, at the price of 10 cents, a unit, comprising one fully paid common share and one-half of a non-transferable agent share purchase warrant; each whole agent share purchase warrant will entitle the holder to acquire one additional common share at the price of 12.5 cents. The agent warrants and any agent share purchase warrants that may be issued pursuant to exercise of an agent warrant, if not exercised, will expire on the maturity date. As previously announced, it is anticipated that, subject to compliance with relevant regulatory provisions, certain insiders will participate in this placement, in which case the company will rely on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions. Funds raised in this placement will be allocated to redemption of any Series I notes that are not surrendered by way of subscription for Series IV notes, continuing development of the company's leading-edge SIAscopy on the DermSecure telemedicine platform, building out the launch of its technology into the occupational health marketplace and general corporate purposes.

About MedX Health Corp.

MedX Health, headquartered in Ontario, Canada, is a data-enabled medical-technology company specializing in non-invasive skin-screening and teledermatology through its proprietary SIAscopy imaging technology and DermSecure platform. The company focuses on improving early detection of skin cancer and expanding digital dermatology and skin care services in investigational (that is, contract research organizations) and for beauty and aesthetics sponsors and operators. Its proprietary SIAscopy technology, integrated into the DermSecure platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables health care professionals to quickly and accurately assess suspicious moles, lesions and other skin conditions through its proprietary imaging technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure. SIAscopy is the only technology capable of the simultaneous, non-invasive measurement of the concentration and spatial distribution of melanin, hemoglobin and collagen in the epidermis and dermis of human skin.

We seek Safe Harbor.